Oryzon Genomics Management

Management Kriterienprüfungen 2/4

Oryzon Genomics' CEO ist Carlos Manuel Arjol , ernannt in Jan 2000, hat eine Amtszeit von 24.58 Jahren. besitzt direkt 4.61% der Aktien des Unternehmens, im Wert von €5.09M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.5 Jahre bzw. 8.8 Jahre.

Wichtige Informationen

Carlos Manuel Arjol

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	24.7yrs
Eigentum des Geschäftsführers	4.6%
Durchschnittliche Amtszeit des Managements	5.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	8.8yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Carlos Manuel Arjol

24.7yrs

Amtszeit

€58,000

Vergütung

Dr. Carlos Manuel Buesa Arjol Co-Founded Oryzon Genomics S.A. in 2000 and has been its Chairman and Chief Executive Officer since 2001 and serves as its President and served as its Member of Financial Advi...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Carlos Manuel Arjol	Co-Founder	24.7yrs	€58.00k	4.61% € 5.4m
Enric Condomines	Director of Operations	4.3yrs	keine Daten	keine Daten
Jordi Pey	Chief Scientific Officer	3.7yrs	keine Daten	keine Daten
Xavier Ribera	Head of Internal Audit & Compliance	no data	keine Daten	keine Daten
Emili Cortada	Chief Business Development Officer	no data	keine Daten	keine Daten
Neus Bernado	Chief Intellectual Property Officer	13yrs	keine Daten	keine Daten
Michael Ropacki	Chief Medical Officer of CNS	3.7yrs	keine Daten	keine Daten
Sonia Paloma Bezon	Chief of Clinical Operations	6.9yrs	keine Daten	keine Daten
Augusto Rubio	Secretary	no data	keine Daten	keine Daten

5.6yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: 0RDBDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.5 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Carlos Manuel Arjol	Co-Founder	23.7yrs	€58.00k	4.61% € 5.4m
Howard Fillit	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Isabel Aguilera Navarro	Independent Director	8.8yrs	€7.00k	keine Daten
Lori Kunkel	Member of Scientific Advisory Board	6.6yrs	keine Daten	keine Daten
Manuel López-Figueroa	Lead Independent Director	4.3yrs	keine Daten	keine Daten
Josep Echarri Torres	Director	22.6yrs	€6.00k	1.98% € 2.3m
Tamara Maes	VP of the Board & President of Scientific Advisory Board	24.7yrs	€58.00k	3.96% € 4.6m
Ramon Ramon	Independent Director	8.8yrs	€7.00k	0.029% € 33.9k
Leon Hooftman	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Antonio Melero	Independent Director	8.8yrs	€7.00k	keine Daten
Felipe Cardoso	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Jose Molinuevo	Member of Scientific Advisory Board	no data	keine Daten	keine Daten

8.8yrs

Durchschnittliche Betriebszugehörigkeit

66yo

Durchschnittliches Alter

Erfahrener Vorstand: 0RDBDie Vorstandsmitglieder gelten als erfahren (8.8 Jahre durchschnittliche Amtszeit).

Oryzon Genomics Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Insufficient new directors

Oryzon Genomics S.A. Announces Appointment of Douglas V. Faller as Global Chief Medical Officer

Oryzon Genomics S.A. Announces Executive Changes

Recent updates

No longer forecast to breakeven

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

No longer forecast to breakeven

Oryzon Genomics, S.A. Announces Presentation of Final Data from Portico, Vafidemstat's Global Phase IIb Trial in Borderline Personal Disorder, at the 37th ECNP Annual Conference

Oryzon Genomics S.A. Presents Preliminary Data from Ongoing Phase Ib Frida Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory Flt3-Mut Aml Patients At Eha-2024

Forecast breakeven date moved forward to 2025

Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat

Forecast breakeven date pushed back to 2026

New minor risk - Share price stability

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

New major risk - Revenue and earnings growth

New minor risk - Profitability

Forecast to breakeven in 2025

Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder

New major risk - Financial position

Oryzon Genomics S.A. announced that it expects to receive €45 million in funding from Nice & Green SA

Oryzon Genomics, S.A. Announces Last Patient Last Visit in Its Phase IIb Portico Study for Borderline Personality Disorder

Oryzon Genomics, S.A. Presents Blinded Aggregated Safety Data from Vafidemstat's Ongoing Phase IIB Portico Trial in Borderline Personal Disorder

New major risk - Financial position

Oryzon Genomics, S.A. Reports New Preliminary Blinded Aggregate Safety Data from Its Ongoing Phase IIb Portico Trial

Oryzon Genomics, S.A. Presents Positive Preclinical Data of Ory-4001 for the Treatment of Charcot-Marie-Tooth Disease Presented At the 2023 Peripheral Nerve Society Annual Meeting

Insufficient new directors

Oryzon Genomics, S.A. to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease At the 2023 Peripheral Nerve Society Annual Meeting

Forecast to breakeven in 2025

Oryzon Genomics S.A. announced that it has received €1.800407 million in funding

ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

Oryzon Genomics S.A. announced that it expects to receive €20 million in funding from Nice & Green SA

Oryzon Genomics S.A. At Eha-2022: Iadademstat 42-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University

Oryzon Genomics S.A. Announces Appointment of Douglas V. Faller as Global Chief Medical Officer

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

ORYZON Announces Approval for Serbian Arm of PORTICO, Vafidemstat’s Phase IIb Trial in Borderline Personality Disorder

Oryzon Genomics S.A. Presents Iadademstat 36-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Announces $1 Million Grant from Kabuki Syndrome Philanthropists to Support A Precision Medicine Phase I/Ii Trial with Vafidemstat

First half 2021 earnings released: €0.019 loss per share (vs €0.026 loss in 1H 2020)

Oryzon Genomics S.A. Receives Approval to Start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia

Oryzon Genomics, S.A. Announces FDA Approval of IND for Portico, Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

ORYZON Presents Iadademstat ALICE 30-Month Data at EHA-2021, Confirming Positive and Robust Efficacy in Combination with Azacitidine in AML

ORYZON to Present New Clinical Data

Oryzon Genomics, S.A. Announces Successful pre-IND Meeting with FDA for the Clinical Development of vafidemstatin Borderline Personality Disorder

Oryzon Genomics S.A. Presents Vafidemstat 12-Month Clinical Data from Its Phase IIa Clinical Trials

Full year 2020 earnings released

New 90-day high: €3.84

Oryzon Genomics S.A. Launches Pioneering Schizophrenia Precision Medicine Study in Collaboration with Columbia Psychiatry

New 90-day high: €3.18

New 90-day low: €2.69

Oryzon Genomics S.A. to Present Further Positive Efficacy Data From Iadademstat ALICE Phase IIa Trial at the 62nd Congress of the American Society of Hematology

Oryzon Genomics, S.A. Receives Approval to Start PORTICO Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

Oryzon Genomics S.A. Announces Executive Changes

Third quarter earnings released

New 90-day low: €2.71

Oryzon Genomics S.A. has completed a Follow-on Equity Offering in the amount of €20.00075 million.

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter